Expression VI ( Carolin meets HANNA) Long-Term Survivors

carolinIn Switzerland, every year, approximately 800 women are diagnosed with ovarian, fallopian tube or peritoneal cancer.

These diseases are among the most complicated and prognostically unfavorable clinical pictures in medicine.

Fortunately, in daily clinical practice, we increasingly meet women diagnosed with ovarian, fallopian tube or peritoneal cancer who have been disease-free for over five years, so-called long-term survivors. As a result hereof, clinical research has gained interest in these patients, with or without a recurrence of cancer, with a long standing disease-free period. However, as of today, only little scientific data is available on this specific group of pateints.

The Expression VI-Carolin meets HANNA- study specifically aims to collect scientific data on  long-term survivors diagnosed with ovarial cancer, to indentify specific factors, which are characteristic for this exceptional group of patients.

Expression VI -Caroline meets HANNA- Holistic Analysis of loNgterm survivors with ovariaN cAncer (ENGOT-ov40/NOGGO S13/Swiss-GO-1).

Next to biological and immunological factors, the study takes into account the patients´ quality of life and resilience, as well as their lifestyle in terms of diet, physical activity and sleep.

Are you or belongs your patient to this extraordinairy group of long-term survivors with ovarian, fallopian tube or peritoneal cancer, and would you or your patient like to participate in this study?

Join in!

If you participate you will get a feedback on nutrition, physical activity and resilience (ability to manage crises). With your participation you will enable that other patients can benefit from new scientific findings. For additional information, as on how to participate, please contact the Swiss-GO office or ask your treating physician to contact the Swiss-GO office:  This email address is being protected from spambots. You need JavaScript enabled to view it..

Swiss-GO represents the Swiss participating sites in this ENGOT study. In Switzerland currently, over 103 patients are taking part in the study (as of April 2020)

This project has been developed by the North-East German Society for Gynecological Oncology and the European Center of Excellence for Ovarian Cancer of the Charité – Universitätsmedizin Berlin. This project is supported by the German Foundation for Ovarian Cancer, the DIWA network, and is carried out worldwide as part of the international study groups GCIG and ENGOT.

Research Partners:


Swiss GO Trial Group
Gynecological Oncology
Hospital for Women
University Hospital Basel
Spitalstrasse 21
CH-4031 Basel

Contact Info

Phone: +41 61 265 75 00
Fax:      +41 61 265 93 22

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Swiss GO Logo
© Swiss GO Trial Group, Basel